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At the outset, I thank the Tuberculosis 
Association of India for selecting me for this 
Award. I am accepting this honour with the 
blessings of all the veterans and learned 
scholars in the field of tuberculosis in India 
for my future guidance. 
The subject I have chosen for the review is 
“Drug Resistance” which as you all know, is 
of most contemporary interest. The review 
covered all aspects of drug resistance in 
tubercle bacilli, particularly the genetic, 
biochemical and bacteriological aspects and 
also dealt briefly on the epidemiological control 
of tuberculosis. Time does not permit me to 
d e a l  w i t h  a l l  t h e  a s p e c t s  i n  d e t a i l .  
Hence, I am constrained to limit to a very 
brief presentation of all the salient aspects of 
my review. 
Before one goes further, one should define 
what he means by the various terms he has 
been using. By sensitive strains one means 
those strains of tubercle bacilli which normally 
respond to low concentrations of the drugs in 
a uniform manner. In contrast, resistant strains 
are those which can grow in higher concentra-
tions of the drug and they are, therefore, 
definitely different from sensitive strains. 
According to Mitchison (1961), resistance can 
be defined as a decrease of sensitivity to the 
drug of sufficient degree to be reasonably 
c e r t a i n  t h a t  t h e  s t r a i n  o b t a i n e d  i s  
different  f rom a sample of  wild s t rains  
of tubercle bacilli  that have never come 
in contact with the drug. Primary drug 
resistance is that which is caused by infection 
from an outside source of drug resistant 
tubercle bacilli. In other words, patients who 
are supposed to have primary drug resistance 
should, from the beginning, have resistant 
bacilli without treatment. In contract, acquired 
drug resistance is the one which has resulted 
due to faulty management of treatment of the 
patients, who had originally sensitive tubercle 
bacilli. However, in practice, it is not easy to 
decide whether a patient is having primary or 
acquired drug resistance because it takes a 
fantastic amount of checking on the possibility 
of previous, but unreported treatment, to really 
come to a fairly pure untreated group of 
patients. It is, therefore, necessary to view 
the results of many of the so-called primary 
* Paper presented at the   Tuberculosis   and   Chest 
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drugs resistance Surveys in the world as report-
ing not true primary drug resistance, but a 
mixture of it with some unknown amount of 
undisclosed acquired drug resistance. Such a 
type of drug resistance is tentatively termed as 
“initial drug resistance”. 
Let us now go into some genetic aspects of 
drug resistance. Two mechanisms have been 
suggested for the development of resistance. 
The first, a process of genetic selection of 
natural resistant variants from a population 
that is predominantly susceptible. These 
variants arising from genetic mutation become 
more numerous as susceptible cells are inhibited 
by the drug. The second, a process of adapta-
tion or adjustment by which susceptible cells, 
in response to a noxious environment, alter 
their metabolic processes in a manner that 
enables them to survive in its presence. There 
has been a great controversy in the past two 
decades as to which of these two theories can 
explain the origin of drug resistance. Fairly 
convincing evidence is forthcoming in recent 
years to favour the genetic mutation theory of 
the origin of drug resistance, though the 
possibility of other mechanisms has never been 
completely excluded. Bryson and Demerec 
(1950, 1955) and Bryson and Sybalski (1955) 
after prolonged study of streptomycin and 
isoniazid resistance of tubercle bacilli, came to 
the conclusion that genetic variation or 
mutation plays a very important part in the 
emergence of resistant strains than phenotypic 
adaptation. They have distinguished two 
major types of drug resistance (1) the so-called 
“penicillin-type” in which resistance appears 
in a series of multiple genetic steps and (2) 
single step mutation to a high level of resis-
tance. Resistance to streptomycin and isoniazid 
is believed to develop by single step mutation. 
There are other findings in literature which 
also support the mutation theory. These 
include the occurrence of resistant organisms 
before exposure to the drug as shown by 
Schaeffer (1963) using Lederberg’s replica 
planting technique, the occurrence of sponta-
neous mutants, at the rate of 1 in 105 for 
isoniazid and 1 in 106 for streptomycin 
resistance; by the occurrence of permanent and 
irreversable changes and the experimental 
findings of transfer of genetic material by 
transformation and transduction. (Tsukamura 
1960, Watanabe and Fukasawa 1961a, 1961b). 
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Let us now proceed to the mechanisms  of 
drug resistance.    There are several mechanisms 
postulated,   but for our discussion,   we   are 
confining   to   the   3    most    important   ones, 
namely (1) difference in uptake   of  the   drugs 
(2) insusceptible mechanisms  and  (3)  destruc-
tion of the drug.    Considering   the   first one, 
the evidence obtained by Barclay and 
colleagues (1953, 1954) and  by  Youaat   
(1958a,   1958b) using C14 labelled isoniazid 
shows  that there is a difference in the uptake 
of the drug between the sensitive and resistant 
tubercle bacilli, the sensitive bacilli taking 
much  more radio-active drug than the resistant   
bacilli. These authors even suggested that  this 
difference was the result of the alteration of the 
cell permeability. On the other hand, studies  
with C14 labelled PAS did not support the 
same finding. For instance, PAS resistant-
tubercle   bacilli have not only taken the C14 
labelled drug to a much higher degree than the  
sensitive bacilli, but also retained the radio-
active material unchanged after weeks of 
washing; the sensitive strains under these 
conditions lost 50% of the radioactivity. These   
observations on the uptake of the drugs, 
therefore, make it difficult to interpret the 
phenomenon of drug resistance by  a process 
of adsorption, absorption  or penetration.    
Similarly, the available evidence on the 
mechanism   of   the   action   of    these   drugs 
particularly from my own   work carried   out at 
the pharmacology  laboratory,  in  the  Indian 
Institute of Science, Bangalore   and also at the 
National Jewish Hospital at Denver Colorado 
does not warrant an explanation by means  of 
insusceptible mechanism. Evidence of the 
destruction of the drug by the resistant 
tubercle bacilli  on  the  basis  of penicillinase 
activity in   penicillin-resistant  bacteria’ is not 
found in tubercle bacilli   though  there is some 
suggestion by Youmans (1960) and by Toida 
(1962) of the occurrence of   isoniazid destroy-
ing substances in tubercle bacilli. 
There are certain biological variations con-
sequent to the development of drug resistance. 
Considering first the differences in growth rates, 
it was found that certain media are more suit-
able for the development of drug resistant 
bacilli than others. Contrary to the experience 
with other bacteria, the nutritional requirements 
of drug resistant tubercle bacilli, particularly 
those resistant to isoniazid, are more exacting 
than their parent sensitive strains. Thus, 
Middlebrook and his colleagues and Fisher 
found that biotin, bovine albumin fraction V 
and hemin or whole serum were essential for 
the growth of drug-resistant tubercle bacilli. 
Later studies by Knox and co-workers have 
established that catalase had a growth-promo-
ting effect of isoniazid-resistant strains of tubercle 
bacilli which was 100,000 times that of hemin. 
Coming to the differences in some enzymes, 
you all know the classical finding of Middle-
brook that isoniazid-resistant tubercle bacilli 
have diminished catalase activity. Extensive bio-
chemical work carried out by Andrejew and co-
workers (1957) in Paris has shown that the defi-
ciency in the catalase in isoniazid-resistant 
bacilli is due to the deficiency in the capacity to 
synthesise the protein portion of the catalase 
molecule and not due to the hemin or 
cylochrome components. 
However, a number of workers found that 
the correlation between catalase activity and 
isoniazid-resistance is not so good always; fur-
thermore, the atypical mycobacteria which are 
naturally highly resistant to isoniazid, possess 
a very high degree of catalase activity. Studies 
carried out by Andrejew and co-workers (1956, 
1957) and Thirunarayanan and Visher (1957) 
have established the loss of peroxidase activity 
in isoniazid resistance and that better agree-
ment has been found between the loss of pero-
xidase activity and isoniazid resistance, both in 
typical and atypical mycobacteria, than between 
catalase activity and Isoniazid resistance. 
Besides these, deficiencies in dehydrogenase and 
urease activities also were observed. Such defi-
ciencies in enzymes were not noted with other 
drug-resistant bacilli; in fact, streptomycin-
resistant tubercle bacilli were found to show a 
greater salicylate effect than the sensitive 
strains. 
Coming to the third point, several workers 
have established that isoniazid-resistant, catalase 
deficient tubercle bacilli are naturally attenuat-
ed to the guinea-pig. It was also mentioned 
that the ability to infect such animals was not 
changed; the aspect which had changed was the 
ability to initiate a progressive disease. On the 
other hand, these organisms are not attenuated 
to the mouse. The question naturally arises, 
whether man is similar to the guinea-pig or to 
the mouse in this respect. Some workers sug-
gest that these organisms are not dangerous to 
man, where progressive disease attributed to 
them has not been shown to develop. Accord-
ing to the results obtained in the WHO Tuber-
culosis Project in Kenya, their infectivity to 
humans also is remarkably less than that of the 
sensitive organisms. On the other hand, the 
consensus of the opinion of the world experts 
in tuberculosis seems to be that these organisms 
cannot be considered to be attenuated to 
humans. In contrast to the isoniazid-resistant 
bacilli, no attenuation in virulence of strepto-
mycin or PAS resistant tubercle bacilli is obser-
ved; in fact, Zakariadze (1956) found an in-
crease in virulence of streptomycin-resistant 
tubercle bacilli. 
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Having discussed the general biological 
aspects, let me briefly turn on to the techniques 
available for testing drug resistance. Sensitivity 
tests for tubercle bacilli can be classified as 
direct or indirect. In the direct test, the sputum 
concentrate is directly inoculated on the drug-
containing, as well as on to the drug-free control 
slopes; the indirect method consists of first 
isolating or culturing the organisms from the 
sputum with subsequent subcultures onto the 
control and drug-containing medium. The 
direct sensitivity tests can further be classified 
as follows: (1) Middlebrook and Cohn’s method 
using 7H-10 medium in quadruple Felson plates; 
this method is being used in several American 
laboratories; (2) the gradient plates using 
Sybalski’s method using 7H-10 medium; this 
methods is being used by Hobby and her colle-
gues and the Veterans Administration of 
U.S.A.; (3) the other direct sensitivity test pro-
cedures using Lowenstein-Jensen medium in 
universal containers (Mackey, 1964) and by us 
at the Central Laboratory of the ICMR Drug 
Resistance Survey (Devaki et al, 1967). 
The indirect sensitivity tests may also be 
classified into 3 main categories (i) the absolute 
concentration method developed by Meissner 
and her co-workers and used by the U.S. 
Veterans Administration Services; (ii) the resist-
ance ratio method introduced by Mitchison and 
used in all the investigations carried out by the 
Medical Research Council of Great Britain and 
its units in various countries, the controlled 
clinical trials in the Tuberculosis Chemothera-
py Centre, Madras, and in the series of co-
operative investigations on the prevalence of 
drug resistance in India conducted by the 
ICMR, about which you listened yesterday and 
in last year’s conference; (iii) the proportion 
method developed by Canetti and co-workers. 
The relative merits of these techniques, 
especially the indirect tests were discussed in 
several conferences including the one at Ahme-
dabad and I would only briefly discuss some of 
them. 
Direct sensitivity tests are preferred to in-
direct sensitivity tests on the following grounds 
(a) they deal with a more representative cross- 
section of the population present in the patient, 
since all the bacilli in  the biological  specimens 
are obtained in the sample used for inoculation 
(b) preliminary culturing  of biological speci- 
mens in drug-free medium  which  may  permit 
the overgrowth of colonies  that vary in their 
susceptibilities is   avoided.   Subculturing may 
also result in the production of a non-represen- 
tative population with properties  of drug  sus- 
ceptibility entirely different from  those present 
in the original specimen.  This altered composi- 
tion  of sensitive  and resistant   bacilli   would 
give an erroneous impression of original bacte- 
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rial sensitivity and (c) the time required for 
reading the sensitivity test is reduced by about 
4 weeks. On the other hand, the direct sensiti-
vity tests suffer from the criticisim in that they 
are useful only when the sputum contains ade-
quate number of bacilli as shown by direct-
smear positivity, since the results may not be 
reliable when their number in the inoculum is 
scanty. However, recent evidence from the 
Central Laboratory of the ICMR Drug Resist-
ance Survey (Devaki et al, 1967) indicates that 
the direct sensitivity test may still be valuable 
even if the direct smear is negative. According 
to Mitchel and Bell, (1958) the choice between 
the direct and indirect sensitivity test is primarily 
a matter of individual preference. 
Even without the availability of the techni-
ques, we can predict drug resistance by other 
means. For instance, we can predict drug 
resistance pretreatment by a thorough ques-
tioning; a patient who had extensive chemo-
therapy and still positive bacteriologically 
has most certainly, drug resistant organisms. 
However, I may hasten to let you know that 
this is very difficult in practice to assess the 
previous history. During treatment, if a 
patient has had regular treatment for some 
time, say, 6 months, and is still positive on 
smear, he has most probably drug resistant 
tubercle bacilli. Studies carried out at the 
Tuberculosis Chemotherapy Centre, have 
revealed that smears can also be used in 
predicting drug resistance even in controlled 
clinical trials. 
Having discussed the techniques of drug 
resistance, let me briefly touch upon certain 
aspects which are closely related to it. First, 
the microbial persistance where the bacteria 
are not killed by the drugs even though they 
are sensitive to them as demonstrated by the 
in vitro tests. This is supposed to be due 
either to the dominant nature of the organisms 
or the inability of the drugs to reach the sites 
of bacterial proliferation. In man, microbial 
persistance is of great importance because it 
is probably responsible for (a) the fact that 
bacteriocidal activity of drugs on organisms 
in lesions is lower than in actively growing 
cultures in vitro, resulting in the need for a 
lengthy period of treatment, (b) the occurrence 
of relapse (usually due to drug-sensitive 
organisms) even after a prolonged course of 
chemotherapy, such as a year in the treatment 
of pulmonary tuberculosis. Coming to natural 
resistance, it has been mentioned that bovine 
strains of tubercle bacilli are naturally resistant 
to PAS and that anonymous mycobacteria 
are resistant to the standard drug. Even 
among typical human bacilli, those obtained 
from our country have shown some degree 
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of natural resistance to PAS and thiacetazone 
in some parts of India. Coming to cross 
resistance, it has been found that once a 
bacillary population has become resistant to a 
drug, it may happen that this population is 
also resistant to another drug which has some 
chemical resemblance to the first. Cross 
resistance was shown to exist between 
thiacetazone and ethionamide, thiacetazone 
and isoxyl and streptomycin and kanomycin 
etc. 
Let me now proceed to discuss briefly the 
most important and interesting aspect in drug 
resistance, that is, the clinical significance. 
There is sufficient evidence available in litera-
ture to show that in vitro drug resistance 
correlates with clinical response in that patients 
with drug sensitive organisms fare better with 
chemotherapy than the patients with drug 
resistant organisms; this is more pronounced 
in the case of isoniazid resistance. Evidence is 
also forthcoming in recent times that even low 
degrees of drug resistance have clinical signi-
ficance. Let us now discuss the various factors 
responsible for the development of drug 
resistance. These can be classified as biologi-
cal, clinical and sociological. The biological 
factors include (a) initial bacilliary population 
(b) local factors inside the host favourable for 
the multiplication of resistant bacilli (c) presence 
of the drug in insufficient concentration and 
(d) patient’s inactivation status. The clinical 
factors include (a) treatment with single drugs 
(b) inadequate dosage  of the drug  (c)   insuffi- 
cient   duration    (d)     interference   by   occult 
medicine (e)   interference by other   indigenous 
systems   of   medicine,   and   the   sociological 
factors    which   are   most    important in   my 
opinion, are (e) irregularity  in drug-taking (b) 
not following treatment  for the entire   period 
(c) avoidance   of other   exogenous   infections. 
Having perused  the list of some of the  causes 
of drug  resistance,  let us   ponder   over how 
best we could avoid them. 
It has been suggested that (1) double drug 
therapy should be given to all patients suffer-
ing from pulmonary tuberculosis in adequate 
doses of the drugs to which the bacteria are 
susceptible; (2) the duration of chemotherapy 
should be at least for one year and possibly 
more (3) every effort should be bestowed to 
see that the drugs are properly taken in the 
prescribed manner for the prescribed lime and 
(4) there must be no chance of exogenous 
infection with resistant bacilli during the 
course of chemotherapy. The mere fact that 
2 drugs were prescribed does not. however, 
guarantee that they are both taken by patients 
unless they are given in a single catchet or 
tablet. If they are dispensed separately, 
preferential omission of the less acceptable 
drug may occur leading into the development 
of resistance to the drug taken regularly. 
This brings us to the question how drug 
resistance emerges in clinical practice. If 
daily straptomycin and isoniazid in adequate 
doses are given very little emergence of resis-
tance occurs as this treatment ensures about 
99% success. On the other hand, if PAS 
substituted cither of these drug, about 10% of 
the patients develop drug resistance, mainly 
due to the failure of the PAS to prevent emer-
gence of the resistant bacilli to the other 
companion drug, streptomycin or isoniazid. 
Studies carried out at our Centre have 
indicated that when isoniazid alone is prescrib-
ed, drug resistance developed in 2 stages. In 
the first stage, occurring very early in the 
treatment, highly resistant mutants of bacilli 
grew freely whatever the isoniazid dosage but 
mutants of low resistance were prevented from 
growing to an extent depending upon the 
peak isoniazid concentrations in the serum. 
In the second stage, organisms with relatively 
lower resistance continue to multiply though 
still partially inhibited by isoniazid and become 
more resistant, particularly in slow inacti-
vators. 
Let us now briefly touch upon the treat-
ment of drug resistant cases for pulmonary 
tuberculosis. Treatment for such cases 
although not hopeless, leaves much to be 
desired. Depending upon the situation, 
several of the second line drugs are recom-
mended along with the initial treatment drugs 
to which the bacilli are sensitive. There are 
7 or 8 acceptable second line drugs, but their 
cost and instability in tropical conditions pose 
serious limiting factors for their use. Treat-
ment of these failure cases can be considered 
separately under 3 headings as follows: 
(1) If isoniazid-resistance   has not develop 
ed, even though the   bacilli   are   resistant   to 
streptomycin   and   PAS,   a    combination   of 
pyrazinamide and isoniazid is   acclaimed to be 
the   best.    Recently,    following    the   studies 
carried out in   East Africa and in  our   Centre 
and several other places in   India, thiacetazone 
and    isoniazid    combinations   may   also   be 
recommended: 
(2) When    the    bacilli     are   resistant   to 
isoniazid, it is generally believed that any com 
bination  of drugs  will   not   be   satisfactory. 
Streptomycin and   PAS combinations are  nor 
mally prescribed in such cases.   Studies carried 
out at the  Tuberculosis Chemotherapy Centre, 
Madras have  established the value of the com 
bination   of pyrazinamide and streptomycin  in 
such cases; 
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(3) when the tubercle bacilli are resistant 
to all 3 drugs or at least both to isoniazid and 
streptomycin, the situation is highly deplorable, 
especially in a large part of the developing 
world. The drugs to be administered under 
these conditions are the 2nd line drugs which 
the patient can tolerate and to which he is not 
likely to be resistant. Studies carried out at 
the Tuberculosis Chemotherapy Centre have 
indicated that a combination of ethionamide 
and cycloserine is better than thiacetazone and 
cycloserine. It is also believed that the combi-
nation of pyrazinamide and ethionamide is 
probably the best one under these circum-
stances, with a supplement of thiacetazone and 
viomycin, if possible. Furthermore, it is also 
suggested that inclusion of isoniazid as one of 
the drugs in these regimens even though the 
bacilli are resistant to this drug shows some 
more additional benefit. 
While these recommendations are perhaps 
feasible, and therefore can be followed in 
developed countries, it is a matter of serious 
consideration whether these can be applied in 
a developing country like India for the 
following reasons: 
(a) On  economic grounds, it  is definitely 
impossible to  offer  such  a costly treatment to 
every patient with    resistant   organisms;  the 
crippled health budget   is   perhaps not  even 
sufficient to offer a standard  double drug com 
bination  of initial   chemotherapy   for  every 
patient for one year; 
(b) on   grounds   of  economy   of foreign 
exchange, these drugs  are   not   yet imported, 
and,   therefore,   are   mostly   not available in 
India; 
(c) many   institutions   are   not   yet   well- 
equipped to follow the  patients very carefully 
with   the   series   of tests  necessary   to guard 
against   the   onset   of    toxic   manifestations 
usually associated with these drugs. 
Having discussed the various aspects of 
drug resistant, let us touch upon the prevalence 
of infection by drug resistant tubercle bacilli 
in the community. One of the most important 
recommendations of the experts in tubercu-
losis is that every country which is contem-
plating mass chemotherapy programme, 
should assess the prevalence of drug resistance 
in their community. Such information natu-
rally would enable the authorities in the 
country to plan the correct chemotherapy 
programme, as well as arrive at a useful 
information regarding the success of these 
programme.  F o r  w a n t  o f  t i m e  I  a m    
not going to discuss the results of the 2 drug 
resistance surveys which the ICMR has been 
conducting in our country. The results were 
presented by me in last year’s and this year’s 
 
Some authorities (Canetti 1962) consider 
the epidemiological aspects of drug resistance 
separately for developing nations. Though this 
bifurcation of the problem is justified on 
economic grounds, it becomes erroneous when 
we consider the fact that countries become 
closer and closer every day, thanks to the 
efficient international communication and co-
operation we have today. As examples, we can 
refer to the recent finding of Thomas (1963) 
of Miller and co-workers (1966) of the high 
conferences and are too well-known to you. 
On the other hand, I would like to briefly high-
light some of essential requirements of the 
primary drug resistance surveys if the results 
are to be meaningful. These criteria are: (1) 
that reliable bacteriological techniques have 
been used in the investigation (2) the levels of 
drug resistance chosen have been found to be 
clinically meaningful (3) all drug sensitivity 
tests are performed in a single laboratory 
under carefully defined conditions allowing 
precise control of inculum size, medium, 
incubation period and other environmental 
factors (4) the naturally resistant mycobacteria 
like the unclassified or atypical mycobacteria 
have been excluded and (5) perhaps most 
important, the patients from whom the 
resistant bacilli were isolated are those, who 
never had taken any previous antituberculosis 
chemotherapy. I may mention that the ICMR 
Drug Resistance Surveys in the country are in 
our considered opinion fulfilling these criteria 
to a satisfactory level. 
Before I conclude, I would like to briefly 
touch upon some epidemiological aspects of 
drug resistance. While some authorities 
(Canetti 1964) indicate the usefulness of the 
incidence of primary drug resistance as a good 
epidemiological yard stick, prevalence of a 
large component of drug resistant tubercle 
bacilli will complicate the control programme 
and other antituberculosis measures in the 
community. Unlike the situation in U.S.A. and 
other countries, tuberculosis in India may be 
spreading both by exogenous infections as well 
as by endogenous break-downs. While the 
exogenous infection by these drug-resistant 
bacilli is a danger of the present, endogenous 
breakdowns with these organisms is a danger 
for many years to come. Frimodt-Moller 
(1962) rightly expresses considerable concern 
regarding the possible future by saying :’This 
may only be the beginning, being the result of 
infections which took place several years ago, 
How many shall we find in 10 to 20 years 
when those infected today develop their 
tuberculosis disease”. Of course, this sort of 
unfortunate development may be taking place 
in parts of the developing world. 
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incidence of drug resistance in immigrants. It 
is, therefore, necessary to view this problem as 
a threat to the whole world, even though 
temporarily certain areas are hit harder than 
others. Of course, if we aim at eradication of 
tuberculosis in the world at least in the next 
century (certainly it is not even in sight in this 
century!) an all round global attack should be 
launched in all seriousness, right now. 
Finally, considering the actual situation as 
it is existing in India and other developing 
countries, about a quarter to one third of the 
tuberculosis patients when they first report to 
the chest clinics cannot be treated with stan-
dard initial chemotherapy, even if the chemo-
therapy is made available. To this, is to be 
added the influence of poor hygiene, poor 
nutrition, and overcrowding, in enhancing the 
exogenous and endogenous spread of tuber-
culosis. All these factors show us the shocking 
and threatening picture, whether the situation 
degrades to that of the pre-chemotherapeutic 
days. Though some authorities like Dr. 
Meyers (1963) think that the situation does 
not deteriorate to such a level in the developed 
nations, it is worth our serious concern whe-
ther it does in the poorer nations. 
It should also be our most serious endea-
vour as to how best we can correct the weakest 
point in the development of drug resistance, 
that is, the patient and his co-operation to 
treatment. May be the phthisiologists will do 
well to invite the help and advice of socio-
logists and psychologists in this endeavour. 
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